{
    "clinical_study": {
        "@rank": "164631", 
        "arm_group": [
            {
                "arm_group_label": "Risendronate/Cholecalciferol combination", 
                "arm_group_type": "Experimental", 
                "description": "Experimental: Administer Risendronate/Cholecalciferol combination one tablet once a week for 12months."
            }, 
            {
                "arm_group_label": "Risedronate", 
                "arm_group_type": "Active Comparator", 
                "description": "Active comparator: Administer Risendronate one tablet once a week for 12months."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and the safety of Risedronate,\n      cholecalciferol combination tablet in patients with Osteoporosis."
        }, 
        "brief_title": "Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Osteoporosis", 
        "condition_browse": {
            "mesh_term": "Osteoporosis"
        }, 
        "detailed_description": {
            "textblock": "The purpose of this study is to evaluate the efficacy and the safety of Risedronate with and\n      without cholecalciferol on vitamin D status, Bone Mineral Density (BMD) and bone markers."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male osteoporosis patients over 19 years of age\n\n          2. Female osteoporosis patients with menopause\n\n               -  Definition of osteoporosis\n\n                    -  They had a BMD T-score -2.5 or less at mean Lumbar spine(L1-L4), Femoral\n                       neck or total. Or evidence of at least one vertebral fracture\n\n               -  Definition of menopause(can be one of three condition)\n\n                    -  For 12months spontaneous amenorrhea\n\n                    -  For 6months spontaneous amenorrhea with serum FSH(Follicle stimulating\n                       hormone) is 40mlU/mL and over\n\n                    -  6weeks after bilateral ovariectomy whether hysterectomy or not.\n\n        Exclusion Criteria:\n\n          1. Patients with esophagus disorder (i.e:esophagostenosis)\n\n          2. Patients administered with osteoporosis therapy(except calcium, Vit.D\n             medication)within the previous 3 Months\n\n          3. Patients with serum calcium concentrations 8.0mg under\n\n          4. Patients with severe nephropathy (CCr 30mL/min less)\n\n          5. Patients with unable to sit upright or stand for 30minutes"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "1170", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01675297", 
            "org_study_id": "HL_RSNP_401"
        }, 
        "intervention": [
            {
                "arm_group_label": "Risendronate/Cholecalciferol combination", 
                "description": "once a week", 
                "intervention_name": "Risedronate/Cholecalciferol combination", 
                "intervention_type": "Drug", 
                "other_name": "RisenexPlus tablet"
            }, 
            {
                "arm_group_label": "Risedronate", 
                "description": "once a week", 
                "intervention_name": "Risedronate", 
                "intervention_type": "Drug", 
                "other_name": "Sedron 35mg tablet"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cholecalciferol", 
                "Risedronic acid", 
                "Etidronic Acid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Risedronate, cholecalciferol, BMD", 
        "lastchanged_date": "January 17, 2013", 
        "location": {
            "contact": {
                "email": "baby123@naver.com", 
                "last_name": "Ah Rong Choi, CRC", 
                "phone": "8210-2036-4353"
            }, 
            "contact_backup": {
                "email": "nahyun.kang@hanlim.com", 
                "last_name": "Nahyun Kang, CRA", 
                "phone": "822-3489-6298"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "156-755"
                }, 
                "name": "Chung-ang university hospital"
            }, 
            "investigator": {
                "last_name": "Hyoung-Moo Park, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "For 12months, the Multi Center, Randomized, Open-label, Active Controlled Comparative Clinical Study to Assess the Efficacy and the Safety of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis", 
        "overall_contact": {
            "email": "nahyun.kang@hanlim.com", 
            "last_name": "Na Hyun Kang", 
            "phone": "82-2-3489-6298"
        }, 
        "overall_contact_backup": {
            "email": "yrsong@hanlim.com", 
            "last_name": "Young Ran Song", 
            "phone": "82-2-3489-6297"
        }, 
        "overall_official": {
            "affiliation": "Chung-Ang University Hospital", 
            "last_name": "Hyoung-Moo Park, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The change of Bone Mineral Density (BMD) value", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01675297"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "The change of 25OHD(25-hydroxyvitamin D)/PTH(Parathyroid hormone value)", 
            "safety_issue": "No", 
            "time_frame": "6months, one year"
        }, 
        "source": "Hanlim Pharm. Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanlim Pharm. Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}